Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net loss	$ (149,994)	$ (240,219)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	27,640	25,269
Impairment loss	10,402	0
Gain on sale of assets	(2,954)	0
Stock-based compensation expense	586	41,553
Gain on debt forgiveness	(2,750)	0
Change in fair value of warrant and earn-out contingent liabilities	(685)	(54,350)
Deferred tax benefit	(515)	(49,176)
Provision for excess and obsolete inventory	3,634	732
Third party payor reserve release	(6,848)	0
Non-cash lease expense	684	1,112
Amortization of deferred debt issuance costs	387	387
Change in operating assets and liabilities:
Accounts receivable	10,726	5,491
Inventory	682	(5,239)
Accounts payable and accrued expenses	(39,913)	28,557
Other assets and liabilities	(1,371)	(8,618)
Net cash used in operating activities	(150,289)	(254,501)
Investing activities
Consideration on escrow paid for GeneDx acquisition	(12,144)	(127,004)
Purchases of property and equipment	(2,874)	(4,990)
Proceeds from sale of assets	3,887	0
Purchases of marketable securities	(43,935)	0
Proceeds from sales of marketable securities	16,665	0
Development of internal-use software assets	(461)	(6,494)
Net cash used in investing activities	(38,862)	(138,488)
Financing activities
Proceeds from PIPE issuance, net of issuance costs	0	197,659
Proceeds from offerings, net of issuance costs	143,002	0
Finance lease payoff and principal payments	(2,133)	(2,632)
Long-term debt principal payments	(2,000)	0
Exercise of stock options	266	2,223
Net cash provided by financing activities	139,135	197,250
Net decrease in cash, cash equivalents and restricted cash	(50,016)	(195,739)
Cash, cash equivalents and restricted cash, at beginning of period	138,303	401,469
Cash, cash equivalents and restricted cash, at end of period	88,287	205,730
Supplemental disclosures of cash flow information
Cash paid for interest	1,116	1,795
Cash paid for taxes	1,178	487
Stock consideration paid for purchase of business	0	172,000
Purchases of property and equipment in accounts payable and accrued expenses	1,220	1,546
Software development costs in accounts payable and accrued expenses	$ 0	$ 448